Edward Kowalik Email

Scientist . BioAegis Therapeutics

Current Roles

Employees:
13
Revenue:
$2M
About
Commercializing Ground Breaking Discoveries in Inflammation and Infection BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body's natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.
BioAegis Therapeutics Address
675 US Highway One
North Brunswick, NJ
United States
BioAegis Therapeutics Email

Past Companies

BioAegis TherapeuticsScientist
Merck & Co., Inc.Staff Biologist
Elusys Therapeutics, Inc.Associate Scientist 2

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.